| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Bristol-Myers Squibb Company (NYSE:BMY), which announced $4 billion aggregate accelerated share repurchase agreements.
Bristol Myers Squibb recently said that its second-quarter revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and our new product portfolio. Analysts estimated sales of $11.81 billion.
Jenny Harrington of Gilman Hill Asset Management named NNN REIT, Inc. (NYSE:NNN), which announced earnings last week. The company has a 5.6% dividend yield.
NNN REIT recently priced its public offering of $500 million of 5.600% senior unsecured notes due 2033.
Analysts have a consensus Buy rating on NNN REIT, according to Benzinga's analyst ratings data.
Josh Brown of Ritholtz Wealth Management said Toast, Inc. (NYSE:TOST) had a bunch of price-target hikes on the Street following the earnings release. "I am staying long," he added.
Toast reported mixed second-quarter financial results and issued guidance above estimates.
Don’t forget to check out our premarket coverage here
Price Action: Toast shares fell 1.8% to settle at $22.77, while NNN REIT shares slipped 0.1% to close at $39.96 on Thursday. Bristol-Myers Squibb shares gained 1.1% to $61.29 on Thursday.
Check This Out: Fear & Greed Index Remains In 'Greed' Zone Following Inflation Data
Photo: Shutterstock
